These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. MHC class II restricted neoantigen: A promising target in tumor immunotherapy. Sun Z; Chen F; Meng F; Wei J; Liu B Cancer Lett; 2017 Apr; 392():17-25. PubMed ID: 28104443 [TBL] [Abstract][Full Text] [Related]
6. Mutational Landscape and Sensitivity to Immune Checkpoint Blockers. Chabanon RM; Pedrero M; Lefebvre C; Marabelle A; Soria JC; Postel-Vinay S Clin Cancer Res; 2016 Sep; 22(17):4309-21. PubMed ID: 27390348 [TBL] [Abstract][Full Text] [Related]
7. Neoantigens in cancer immunotherapy. Schumacher TN; Schreiber RD Science; 2015 Apr; 348(6230):69-74. PubMed ID: 25838375 [TBL] [Abstract][Full Text] [Related]
8. Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads. Lussier DM; Alspach E; Ward JP; Miceli AP; Runci D; White JM; Mpoy C; Arthur CD; Kohlmiller HN; Jacks T; Artyomov MN; Rogers BE; Schreiber RD Proc Natl Acad Sci U S A; 2021 Jun; 118(24):. PubMed ID: 34099555 [TBL] [Abstract][Full Text] [Related]
9. Landscape of Tumor Antigens in T Cell Immunotherapy. Ilyas S; Yang JC J Immunol; 2015 Dec; 195(11):5117-22. PubMed ID: 26589749 [TBL] [Abstract][Full Text] [Related]
10. Preface: More than two decades of modern tumor immunology. Galluzzi L; Rudqvist NP Methods Enzymol; 2020; 632():xxiii-xlii. PubMed ID: 32000917 [No Abstract] [Full Text] [Related]
11. Targeting neoantigens to augment antitumour immunity. Yarchoan M; Johnson BA; Lutz ER; Laheru DA; Jaffee EM Nat Rev Cancer; 2017 Apr; 17(4):209-222. PubMed ID: 28233802 [TBL] [Abstract][Full Text] [Related]
12. The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer. Ward JP; Gubin MM; Schreiber RD Adv Immunol; 2016; 130():25-74. PubMed ID: 26922999 [TBL] [Abstract][Full Text] [Related]
13. Gene-expression profiling to predict responsiveness to immunotherapy. Jamieson NB; Maker AV Cancer Gene Ther; 2017 Mar; 24(3):134-140. PubMed ID: 27834354 [TBL] [Abstract][Full Text] [Related]
14. Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine. Nebot-Bral L; Brandao D; Verlingue L; Rouleau E; Caron O; Despras E; El-Dakdouki Y; Champiat S; Aoufouchi S; Leary A; Marabelle A; Malka D; Chaput N; Kannouche PL Eur J Cancer; 2017 Oct; 84():290-303. PubMed ID: 28846956 [TBL] [Abstract][Full Text] [Related]
15. Lack of shared neoantigens in prevalent mutations in cancer. Ragone C; Cavalluzzo B; Mauriello A; Tagliamonte M; Buonaguro L J Transl Med; 2024 Apr; 22(1):344. PubMed ID: 38600547 [TBL] [Abstract][Full Text] [Related]
16. Neoantigen vaccine: an emerging tumor immunotherapy. Peng M; Mo Y; Wang Y; Wu P; Zhang Y; Xiong F; Guo C; Wu X; Li Y; Li X; Li G; Xiong W; Zeng Z Mol Cancer; 2019 Aug; 18(1):128. PubMed ID: 31443694 [TBL] [Abstract][Full Text] [Related]
17. The double-edged sword of cancer mutations: exploiting neoepitopes for the fight against cancer. Alvarado-Cruz I; Meas R; Paluri SLA; Carufe KEW; Khan M; Sweasy JB Mutagenesis; 2020 Feb; 35(1):69-78. PubMed ID: 31880305 [TBL] [Abstract][Full Text] [Related]
18. Cancer Neoantigens. Schumacher TN; Scheper W; Kvistborg P Annu Rev Immunol; 2019 Apr; 37():173-200. PubMed ID: 30550719 [TBL] [Abstract][Full Text] [Related]
19. Unique tumor antigens: evidence for immune control of genome integrity and immunogenic targets for T cell-mediated patient-specific immunotherapy. Sensi M; Anichini A Clin Cancer Res; 2006 Sep; 12(17):5023-32. PubMed ID: 16951217 [TBL] [Abstract][Full Text] [Related]
20. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives. Thomas R; Al-Khadairi G; Roelands J; Hendrickx W; Dermime S; Bedognetti D; Decock J Front Immunol; 2018; 9():947. PubMed ID: 29770138 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]